Randomised clinical trial: the efficacy and safety of oltipraz, a liver X receptor alpha-inhibitory dithiolethione in patients with non-alcoholic fatty liver disease.
Won KimB G KimJ S LeeC K LeeJ E YeonM S ChangJ H KimH KimS YiJ LeeJ-Y ChoS G KimJ-H LeeYun Joon KimPublished in: Alimentary pharmacology & therapeutics (2017)
Twenty-four-week oltipraz treatment significantly reduced the liver fat content in patients with NAFLD. Clinicaltrials.gov (NCT01373554).